ANEMIA. Oral iron. IV iron gluconate (order set #233)
|
|
- Duane Chase
- 5 years ago
- Views:
Transcription
1 PREVENTION
2 ANEMIA Oral iron IV iron gluconate (order set #233)
3 TRANSEXAMIC ACID Efficacy of IV TXA in Reducing Blood Loss After Elective C-section: Prospective, Randomized, Double-blind, Placebo Controlled Study 660 women 330 in each arm 1 g TXA IV over 5 minutes at least 10 minutes prior to skin incision Oxytocin given after delivery
4 TXA Mean blood loss less in TXA group TXA group has less patients with >1000 ml bleeds No increase in thrombotic events
5
6
7
8
9
10
11
12
13
14
15
16
17 DIC AND TRANSFUSION
18 DIC DIAGNOSIS Depends on the appropriate test results in the proper clinical setting
19 DIC ETIOLOGIES Sepsis (up to 50%) Obstetrical complications Malignancy (up to 20%) Trauma (especially brain and crush) Severe toxins (snakes) Immunologic reaction (incompatible blood) Organ destruction (acute pancreatitis) Vascular abnormalities
20 OB DIC Acute Hemorrhagic DIC Placental abruption (50%) Eclampsia (up to 7%) Amniotic fluid embolus (50%) HELLP (20 to 84%) Eclampsia Acute fatty liver of pregnancy Massive Hemorrhage Septic abortion
21 DIC Activation of BOTH procoagulant and fibrinolytic pathways leading to thrombosis and bleeding Diverse etiologies
22 DIC Two PARADOXICAL clinical problems Tissue injury caused by disseminated microvascular thrombosis (macro too) Hemorrhage caused by consumption of coagulation factors and accelerated fibrinolysis Thrombosis AND Hemorrhage
23 DIC Clinical features ACUTE CHRONIC
24 DIC ACUTE Usually hemorrhage and thrombosis Diffuse bleeding Multi-organ failure Skin necrosis
25 DIC Major bleeding occurs in a minority (5-12%) of patients More common is organ failure secondary to intravascular thrombi
26 Placental abruption DIC The degree of placental separation tends to correlate with the severity of DIC The leakage of thromboplastin-like material (tissue factor) from the placenta may initiate the DIC Amniotic fluid embolism Amniotic fluid also can initiate the DIC
27 DIC DIAGNOSIS Diagnosis of DIC must encompass both clinical and laboratory information that is being continually monitored by repeating both lab tests and the clinical evaluation
28 DIC LABS DIC Profile (Wesley Lab) CBC (WBC, HBG, PLATELET COUNT) PTT PT/INR FIBRINOGEN D-DIMER FSP ORDER TESTS EVERY 30 MINUTES
29 DIC LAB RESULTS WITH ACUTE DIC Decreased platelet count Decreasing fibrinogen (look at trends) Increased PT/INR Increased PTT Increased D-DIMER Increased FSP
30 DIC LAB RESULTS WITH CHRONIC DIC Variable platelet count Normal PT/INR Normal PTT Normal or increased fibrinogen Increased D-DIMER Increased FSP
31 DIC FSP Detects BOTH Fibrinolysis Fibrinogenolysis D-DIMER Detects Fibrinolysis Plasmin degradation crosslinked fibrin
32 DIC FSP and D-DIMER They do NOT differentiate between SYSTEMIC fibrinolysis of DIC and the LOCALIZED fibrinolysis seen with surgery and trauma
33 TREATMENT DIC MOST IMPORTANT Control/correct the underlying triggering pathologic disease
34 TREATMENT DIC SUPPORTIVE CARE VOLUME EXPANSION TO CORRECT HYPOTENSION BLOOD PRODUCTS ONLY IF BLEEDING OR HIGH RISK FOR BLEEDING MBT
35 TREATMENT DIC BLOOD PRODUCTS ONLY IF BLEEDING OR HIGH RISK FOR BLEEDING (e.g. going to surgery) ONLY IF COAGULATION LABS ABNORMAL REPEAT COAG TESTS EVERY 30 MINUTES
36 TREATMENT DIC IF BLEEDING YELLOW blood can be life saving with severe hemorrhage If platelets less than 50,000, then transfuse platelets One plateletpheresis pack = therapeutic dose Transfuse as quickly as possible Keep at room temperature (do NOT put on ice)
37 TREATMENT DIC IF BLEEDING YELLOW blood can be life saving with severe hemorrhage If INR greater than or equal to 2, then transfuse Fresh Frozen Plasma (FFP) Therapeutic dose = 15 to 30 ml per kg (3-6 units) FFP must be thawed first (30 minutes) Transfuse as quickly as possible Blood warmer can be used Can be stored on ice in cooler
38 TREATMENT DIC IF BLEEDING YELLOW blood can be life saving with severe hemorrhage If fibrinogen less than 200, then transfuse cryo Therapeutic dose = units cryoprecipitate Cryoprecipitate must be thawed first Individual units that need to be pooled (30 minute) Prepooled 5 unit packs (15 minutes) Transfuse as quickly as possible Do not put cryoprecipitate on ice or in refrigerator
39 TREATMENT DIC IF BLEEDING -- RED blood can be life saving with severe hemorrhage -- RED blood used to keep hemoglobin greater than at least 7 (some say 8 to 10) -- Transfuse as quickly as possible (after first 15 minutes) -- Blood warmer can be used -- Blood can be stored on ice in cooler
40 TREATMENT DIC BLOOD PRODUCT USAGE IF BLEEDING YELLOW blood can be life saving with severe hemorrhage If fibrinogen less than 200 transfuse cryo If platelets less than 50,000 transfuse platelets If INR greater than or equal to 2...transfuse FFP RED blood used to keep hemoglobin greater than 7 at least (some say 8 to 10)
41 TREATMENT DIC REMEMBER IF BLEEDING IS ONLY MILD, THEN DO NOT TRANSFUSE JUST BECAUSE THE LABS ARE ABNORMAL BLOOD PRODUCTS JUST BUY YOU TIME TO TREAT THE UNDERLYING PROBLEM ONLY TRANSFUSE IF SIGNIFICANT BLEEDING OR INVASIVE PROCEDURE WITH RISK OF SIGNIFICANT BLEEDING
42 DIC Important to stress that DIC is NOT a disease in itself DIC is ALWAYS secondary to an underlying disorder that activates the coagulation and fibrinolytic systems TREAT THE UNDERLYING PROCESS FIRST
43 TREATMENT DIC If bleeding is uncontrollable Then order MASSIVE BLOOD TRANSFUSION (MBT) PROTOCOL
Coagulopathy Case-2. Andy Nguyen, M.D. 2009
Coagulopathy Case-2 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 42 year-old man brought to the emergency room with severe burn. Patient was rescued by firemen in a serious fire. He had been found unconscious
More informationMassive Haemorrhage J Davies B Ferguson
Massive Haemorrhage J Davies B Ferguson What is Massive Haemorrhage (MH)? Difficult to apply rules as to how much blood loss defines a major haemorrhage. Easier to define how the patient s condition is
More informationREGIONAL AUDIT OF PLASMA PRODUCTS 2016
REGIONAL AUDIT OF PLASMA PRODUCTS 2016 Background: In 2010, the East of England RTC carried out an audit of the use of Fresh Frozen Plasma (FFP) in adult patients. With the introductions of trauma networks
More informationAlberta Health Services - Edmonton Zone Massive Hemorrhage Protocol
This document applies to all Covenant and AHS sites. Client Resource 23: Alberta Health Services - Edmonton Zone Regional Laboratory Services This document is applicable at site(s): GNH MIS RAH SGH UAH
More informationCoagulation and postpartum haemorrhage. Peter Collins Cardiff
Coagulation and postpartum haemorrhage Peter Collins Cardiff Definitions and incidence Massive PPH >2500 ml blood loss (4/1000 deliveries in UK) 1 8% hysterectomy, 75% of severe maternal morbidity 1 Other
More informationMajor Burns Debridement Case
Major Burns Debridement Case Disclaimer / Pre-amble These cases have been de-identified to protect the identity of the patient and the treating teams. These are all real cases and real ROTEMs. The individuals
More informationAlternative Haemostatic Agents in the Management of Obstetric Haemorrhage
Alternative Haemostatic Agents in the Management of Obstetric Haemorrhage Clinical Associate Professor Nolan McDonnell School of Medicine and Pharmacology, School of Women s and Infants Health University
More informationMassive Haemorrhage P Donnelly B Ferguson
Massive Haemorrhage P Donnelly B Ferguson What is Massive Haemorrhage (MH)? Difficult to apply rules as to how much blood loss defines a major haemorrhage. Easier to define how the patient s condition
More informationGeneral Principles of. Hemostasis. Kristine Krafts, M.D.
General Principles of Hemostasis Kristine Krafts, M.D. Hemostasis is a balancing act! pro-ting plugs up holes in blood vessels anti-ting keeps ting under control Pro-Clotting Pro-Clotting vessels platelets
More informationHome truths... the clinical use of components in the UK. Jonathan Wallis. Platelets, FFP, Cryoprecipitate
Home truths... the clinical use of components in the UK Platelets, FFP, Cryoprecipitate Jonathan Wallis Mar-01 Mar-02 Mar-03 Mar-04 Mar-05 Mar-06 Mar-07 Mar-08 Mar-09 Mar-10 Mar-11 Mar-12 E&N.Wales Platelet
More informationApplying ROTEM to the Management of Bleeding in Trauma
Applying ROTEM to the Management of Bleeding in Trauma Sandro Rizoli, MD PhD FRCSC FACS Professor Surgery & Critical Care Medicine Trauma Program Director Chair Trauma Care Disclosure NONE ROTEM Growing
More informationDisseminated Intravascular Coagulopathy
REVIEW ARTICLE Disseminated Intravascular Coagulopathy Lt Col Rajat Kumar Introduction Disseminated Intravascular Coagulopathy (DIC) is an acquired disorder which, in its mildest form is only an aberration
More informationLocal vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors
Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help
More informationLABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency
More informationManaging Massive Transfusions in diverse Patient Populations in a Non-Metropolitan Area
Managing Massive Transfusions in diverse Patient Populations in a Non-Metropolitan Area SHAUNA M.M. STURGILL, LAURIE GILLARD LEARNING OBJECTIVES 1. Compare and contrast massive transfusion protocols for
More informationPlatelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis
1 Nadanotes.com 2 Nadanotes.com 3 Nadanotes.com Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis Clotting
More informationShintaro Makino 1,2, Satoru Takeda 1,2, Takao Kobayashi 1,3,MakiMurakami 1,4, Takahiko Kubo 1,5, Toshiyuki Hata 1,6 and Hideaki Masuzaki 1,7.
doi:10.1111/jog.12708 J. Obstet. Gynaecol. Res. Vol. 41, No. 8: 1155 1160, August 2015 National survey of fibrinogen concentrate usage for postpartum hemorrhage in Japan: Investigated by the Perinatology
More informationBlood transfusion in special situations and poly-trauma. Dr Marina Karakantza Consultant Haematologist in Transfusion Medicine, LTHT
Blood transfusion in special situations and poly-trauma Dr Marina Karakantza Consultant Haematologist in Transfusion Medicine, LTHT Uncontrolled bleeding is a major preventable cause of death in trauma
More informationBlood Product Utilization
Who gets what & when Why not to give blood? Volume Expander For specific number (except as related to procedures) To patients with religious objections to blood transfusions Blood given only when necessary
More informationPostpartum Haemorrhage make sure you give enough fibrinogen!
Postpartum Haemorrhage make sure you give enough fibrinogen! Disclaimer / Pre-amble These cases have been de-identified to protect the identity of the patient and the treating teams. These are all real
More informationRed Cell Transfusion LESSONS FROM TRAUMA
Red Cell Transfusion LESSONS FROM TRAUMA Sandro Rizoli, MD PhD FRCSC FACS Professor Surgery & Critical Care Medicine Trauma Program Director Chair Trauma Care Disclosure KCI Canada CSL Behring NovoNordisk
More informationClinical Use of Plasma for Transfusion. Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School
Clinical Use of Plasma for Transfusion Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School PLASMA PRODUCTS FOR TRANSFUSION Fresh Frozen Plasma (FFP) Thawed Plasma
More informationCategory Storage Shelf Life Additional Criteria
CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.
More informationManejo de la transfusión de plaquetas. Ileana López-Plaza, MD
Manejo de la transfusión de plaquetas Ileana López-Plaza, MD Thrombocytopenia Common in ICU setting 25-38% with< 100,000/µL 2-3 % with < 10,000/µL Common etiologies Drug-induced: heparin, antibiotics,
More informationSignificant Improvement In The Management Of Major Obstetric Haemorrhage With A Rotem Guided Algorithm Using Fibrinogen Concentrate
Significant Improvement In The Management Of Major Obstetric Haemorrhage With A Rotem Guided Algorithm Using Fibrinogen Concentrate Dr Shubha Mallaiah Consultant Anaesthetist Clinical Lead for Blood Transfusion
More informationCryoprecipitate audit within six centres in New Zealand.
Cryoprecipitate audit within six centres in New Zealand. Final Report Audit data collated by: Rachel Donegan : Auckland Rebecca Charman: Manukau Christopher Corkery : Hamilton Catherine Hammond :Wellington
More informationCoagulation in perspective: Blood management. Objectives
Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.
More informationREVIEW OF TRANEXAMIC ACID IN TRAUMA
REVIEW OF TRANEXAMIC ACID IN TRAUMA At the bottom of this article are the links to a couple of pretty good recent reviews about the current state of TXA. But first a bit of background. Coagulopathy in
More informationDisclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications
Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label
More informationFactor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs
Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Call from OR! Scenario -1 Patients is bleeding out! Don t ask why, what rate what s been done! We need blood now! What kind of
More informationUse of ROTEM from the Laboratory Perspective. A/Prof David Roxby SA Pathology
Use of ROTEM from the Laboratory Perspective A/Prof David Roxby SA Pathology What s the Problem? Constant changes in treatment recommendations Lack of good evidence to guide practice Variations in clinical
More informationIndex. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108
A Accuracy, 6, 7, 15, 46, 52, 53, 61, 75, 100, 143, 144, 149, 166, 176, 178 Acquired coagulation disorders, 111 115 Acquired platelet disorders, 99 108 ACT. See Activated clotting time (ACT) Activated
More informationAcute Traumatic Coagulopathy
Jean-Francois Pittet, M.D. Depts of Anesthesia and Surgery Cardiovascular Research Institute University of California San Francisco Acute Traumatic Coagulopathy Plan 1. Description of the coagulation system
More informationEDUCATIONAL COMMENTARY MASSIVE TRANSFUSION PROTOCOL
EDUCATIONAL COMMENTARY MASSIVE TRANSFUSION PROTOCOL Commentary provided by: Kathleen Trudell MLS (ASCP) CM SBBCM University of Nebraska Medical Center Division of Medical Laboratory Science College of
More informationROZAIMAH ZAIN-HAMID. Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara
ROZAIMAH ZAIN-HAMID Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara Drugs Used in Disorders of Coagulation Fibrinolytic drugs Anti-thrombotic thrombotic drugs
More informationEmergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s
Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency Hemostasis Testing Patients actively bleeding
More informationDisseminated Intravascular Coagulation: Laboratory Support for Management and Treatment
Disseminated Intravascular Coagulation: Laboratory Support for Management and Treatment Virginia R. Fisher, BS, MT(ASCP), 1 Mary K. Scott, BS, MLS(ASCP) CM, 1 Christine A. Tremblay, BS, MLS(ASCP) CM, 1
More informationBlood Component Therapy and Apheresis
Blood Component Therapy and Apheresis Dr. Debasish Gupta Program Director, CHF International TRANSFUSION THERAPY Used primarily to treat two conditions Inadequate oxygen carrying capacity because of anemia
More informationPrimary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system
Primary hemostasis Vascular endothelium Vasoconstriction : local tissue factor, nervous system Platelet Plug Platelet Adhesion Platelet Activation Platelet Aggregation Platelet Plug Formation Secondary
More informationChanges in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase
Clinical Hemorheology and Microcirculation 23 (2000) 213 218 213 IOS Press Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase Lirong Jin
More informationImplementation of massive transfusion protocols to guide practice in severe bleeding- is your institution ready?
Implementation of massive transfusion protocols to guide practice in severe bleeding- is your institution ready? Ryan Zarychanski MD MSc University of Manitoba Sections of Hematology and Critical Care
More informationUsing TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS
Using TEG in the ED, OR, and ICU Don H. Van Boerum, MD, FACS Trauma Surgeon, Director of Surgical Critical Care, Co-Director of Shock Trauma ICU, Intermountain Medical Center, Intermountain Healthcare
More informationBlood Component Preparation and Therapeutic Utilization
Blood Component Preparation and Therapeutic Utilization Prof. A. Pourazar Immunohematologist and Transfusion medicine School of Medicine, Isfahan University Of Medical Science IRAN Red Blood cells, Platelets
More informationPrincess Alexandra Hospital Emergency Department. Clinical Procedure. 1 Introduction
Princess Alexandra Hospital Emergency Department Clinical Procedure Trauma, Resuscitation Review Officer: Glenn Ryan 1 Introduction Version no: 1 Approval Date: 16/07/2014 Review Date: 16/07/2016 Authority:
More informationPlatelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.
Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin
More informationClinical Procedure. ROTEM Trauma, Resuscitation. Princess Alexandra Hospital Emergency Department. 1 Introduction
Princess Alexandra Hospital Emergency Department Clinical Procedure Trauma, Resuscitation Review Officer: Glenn Ryan 1 Introduction Version no: 1 Approval Date: 16/07/2014 Review Date: 16/07/2016 Authority:
More informationMassive Transfusion Protocol (MTP)
POLICY Massive Transfusion Protocol (MTP) POLICY STATEMENT This protocol aims to standardize the transfusion of large volumes of blood products in patients sustaining significant hemorrhage. REASON FOR
More informationDisclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018
Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested
More informationPharmacotherapy Resuscitation in Acute Traumatic Coagulopathy: Ready for Prime Time? September 29, 2017
Pharmacotherapy Resuscitation in Acute Traumatic Coagulopathy: Ready for Prime Time? September 29, 2017 Martha Evans, PharmD PGY-1 Pharmacy Resident Dell Seton Medical Center martha.evans@ascension.org
More informationPlasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.
Test Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Karen A. Moffat BEd, MSc, ART, FCSMLS(D) Technical Specialist, Coagulation, HRLMP Assistant Professor, Department of
More informationImproving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm
Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Summer Syed (local PI) Keyvan Karkouti Deputy Anesthesiologist-in-Chief, Toronto General Hospital, University Health
More informationAdv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file:
Adv Pathophysiology Unit 4 Page 1 of 10 Learning Objectives for this file: Topics include structure & function of: 1. Coagulation process platelets, clotting factors 2. Coagulation cascade formation of
More informationWhat Can We Learn from Animal Models of Coagulopathy and Bleeding (about plasma transfusion)?
Test What Can We Learn from Animal Models of Coagulopathy and Bleeding (about plasma transfusion)? William Sheffield Associate Director, Research CBS Centre for Innovation, and Professor, Pathology and
More informationTRANSFUSION MANAGEMENT OF MASSIVE HAEMORRHAGE
POLICY AND PROCEDURE ON TRANSFUSION MANAGEMENT OF MASSIVE HAEMORRHAGE IN THE CORK UNIVERSITY HOSPITAL Reference Number: PPG-CUH-CUH-210 Revision No: 01 Review Cycle: 2 years Author (Lead): Dr Oonagh Gilligan
More informationBasic coagulation applications and case studies
Basic coagulation applications and case studies Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 Agenda Overview about 3 major phases
More informationCoagulation Mechanisms Dr. Nervana Bayoumy
Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand
More informationThe Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli
The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management Elham Khalaf Adeli Overview PBM, bleeding management, Coagulation POC Testing Review of laboratory conventional coagulation
More informationEDUCATIONAL COMMENTARY D-DIMER UPDATE
EDUCATIONAL COMMENTARY D-DIMER UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing
More informationManagement of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015
+ Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Disclosures Off label use of PCC and apcc will be discussed My centre participates
More informationProcedure. Applies To: UNM Hospitals Responsible Department: Transfusion Medicine Effective date: 05/24/2018
Title: Pediatric Massive Transfusion Protocol Procedure and Information Applies To: UNM Hospitals Responsible Department: Transfusion Medicine Effective date: 05/24/2018 Procedure Patient Age Group: (
More informationType of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis.
Coagulation disorders induced by L-asparaginase: correction with and without fresh-frozen plasma Glasmacher A, Kleinschmidt R, Unkrig C, Mezger J, Scharf R E Record Status This is a critical abstract of
More informationUpon completion of the Clinical Hematology rotation, the MLS student will be able to:
Clinical Performance Objectives in Clinical Hematology Department of Medical and Research Technology University of Maryland School of Medicine Spring 2015 Upon completion of the Clinical Hematology rotation,
More informationLaboratory Monitoring of Anticoagulation
Michael Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Learning Objectives Explain the role of common laboratory tests used in monitoring of anticoagulation therapy.
More informationThese handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask
More informationDisclosures. I have received research funding from: I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Boehringer Ingelheim
Test Disclosures I have received research funding from: Novo Nordisk CSL-Behring Boehringer Ingelheim I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Baxter The Medicines Company
More informationPatients who Decline Blood Products:- Haematological Aspects of Care. Dr Catherine Flynn Consultant Haematologist CWIUH
Patients who Decline Blood Products:- Haematological Aspects of Care Dr Catherine Flynn Consultant Haematologist CWIUH Bloodless Labour and Delivery in CWIUH! 9000 8000 7000 6000 5000 4000 3000 2000 1000
More informationRiastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.
Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.1; 14 Apr 2016) VI.2 VI.2.1 Elements for a Public Summary Overview of
More informationIntroduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO
Introduction Hemostasis: Tourniquet Test & Bleeding Time Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Hemostasis A series of reactions that function to stop bleeding, maintaining
More informationObstetrical (OB) Hemorrhage Guidelines
Obstetrical (OB) Hemorrhage Guidelines This document has been prepared by the Puget Sound Blood Center Transfusion Safety and Patient Blood Management Department to provide information necessary to obtain
More informationDEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 COAGULATION COMPETENCY EVALUATION FORM STUDENT NAME:
More informationEDUCATIONAL COMMENTARY STRAIGHT TALK ABOUT THE D-DIMER
EDUCATIONAL COMMENTARY STRAIGHT TALK ABOUT THE D-DIMER Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits
More informationAntifibrinolytic Drugs (Aminocaproic Acid and Tranexamic Acid): Treatment Perspectives for Dental Surgery
Curr Oral Health Rep (2015) 2:143 147 DOI 10.1007/s40496-015-0051-1 ORAL MEDICINE (T SOLLECITO, SECTION EDITOR) Antifibrinolytic Drugs (Aminocaproic Acid and Tranexamic Acid): Treatment Perspectives for
More informationUse of Thromboelastography in the Management of the Trauma Patient Rio Grande Trauma Conference
Use of Thromboelastography in the Management of the Trauma Patient Rio Grande Trauma Conference John A. Aucar, MD, MSHI, FACS, CPE EmCare Acute Care Surgery Del Sol Medical Center Associate Professor,
More informationHematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม
Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม Hematotoxin producing snakes Pit vipers (Crotalinae) Malayan pit viper (Calloselasma rhodostoma) Green pit viper (Trimeresurus
More informationNew factor concentrates on the way to the market
New factor concentrates on the way to the market ISCB, Copenhagen, 1 September 2015 John R. Hess, MD, MPH, FACP, FAAAS Professor of Laboratory Medicine and Hematology Medical Director, Transfusion Service,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 29 July 2004 CPMP/BPWG/1089/00 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL INVESTIGATION OF PLASMA
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary
More informationDepartments of Hcematology and Plastic Surgery and the University Department of Medicine, Glasgow Royal Infirmary
ACUTE FAILURE OF H2EMOSTASIS DURING RESECTION FOR INTRA-ORAL CARCINOMA ; ITS TREATMENT BY AMINOCAPROIC ACID By J. F. DAVIDSON, M.B., M.R.C.P.(Ed.)., I. A. MCGREGOR, F.R.C.S., and G. P. McNICOL, M.D., Ph.D.,
More informationVesalius SCALpel : Coagulation. Coagulation
Vesalius SCALpel : Coagulation Coagulation Clotting tests injury attracts platelets chemoattractants: platelet derived growth factor (PDGF), transforming growth factor beta (TGF beta) platelets release
More informationROTEM/TEG. Circulation in trauma: From roadside to bedside. A/Prof David Roxby SA Pathology Transfusion Service South Australia
ROTEM/TEG Circulation in trauma: From roadside to bedside A/Prof David Roxby SA Pathology Transfusion Service South Australia Joint Trauma & ACCUTE SIG Meeting Disclosures CSL National Blood Authority
More informationGuideline for Theraputic Plasma Exchange
Guideline for Theraputic Plasma Exchange Therapeutic plasma exchange (TPE) removes large-molecular-weight substances such as harmful antibodies from the plasma. It is usually carried out using an automated
More informationLaboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016
Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016 Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be
More informationThe evolution of TQIP Best Practices for Massive Transfusion
The evolution of TQIP Best Practices for Massive Transfusion Bryan A Cotton, MD, MPH Associate Professor of Surgery Department of Surgery and The Center for Translational Injury Research University of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 24 June 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 24 June 2009 CLOTTAFACT 1.5 g/100 ml, powder and solvent for solution for injection B/1 (CIP code: 574 971-9) Applicant:
More informationCongenital Fibrinogen Deficiency. Claude Negrier, MD, PhD Hôpital Louis Pradel Université Claude Bernard Lyon 1
Congenital Fibrinogen Deficiency Claude Negrier, MD, PhD Hôpital Louis Pradel Université Claude Bernard Lyon 1 claude.negrier@chu-lyon.fr Afibrinogenaemia Clinical presentation Phenotypic and genotypic
More informationAIMS FELLOWSHIP CURRICULUM GENERAL/CORE LABORATORY IV
AIMS FELLOWSHIP CURRICULUM GENERAL/CORE LABORATORY IV Module Code: GENERAL IV (Compulsory Module) Module Title: Haematology Module Convenor: Mr David Condie, B. App.Sci (QUT), FAIMS,MASM, MBA Senior Scientist
More informationGUIDELINES FOR THE TREATMENT OF CONGENITAL DISORDERS OF FIBRINOGEN. Australian Haemophilia Centre Directors Organisation
GUIDELINES FOR THE TREATMENT OF CONGENITAL DISORDERS OF FIBRINOGEN Australian Haemophilia Centre Directors Organisation November 2010 Disclaimer This document is a general guide to appropriate practice,
More informationCurrent Evidence based management of Massive Haemorrhage
Current Evidence based management of Massive Haemorrhage Kerry Gunn Department of Anaesthesia and Perioperative Medicine Auckland City Hospital Summary A small proportion (4%) need an aggressive approach
More informationEvaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues
Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Kristi J. Smock, MD Associate Professor of Pathology University of Utah Health Sciences Center Medical Director, Hemostasis/Thrombosis
More informationSSAR-SGAR Jahreskongress SAOA Meeting November 7, 2013
SSAR-SGAR Jahreskongress SAOA Meeting November 7, 2013 How can we evaluate clotting? PD Dr. med. Michael Ganter Institute of Anesthesiology and Pain Medicine Conflict of interest statement In the past
More informationTransfus Med Hemother 2009;36:
Transfus Med Hemother 2009;36:419 436 7 Procoagulators 7.1 Fibrinogen 7.1.1 Preparation, Quality Criteria 7.1.2 Active Constituents 7.1.3 Physiological Function 7.1.4 Application 7.1.4.1 Congenital Fibrinogen
More informationAnti- THrombosis with Enoxaparin in intubated Adolescents
Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question
More informationEmerging Use Of Rotational Thromboelastometry (ROTEM) in Trauma Resuscitation. Ashley Millham, CD, BSC CCPA
Emerging Use Of Rotational Thromboelastometry (ROTEM) in Trauma Resuscitation Ashley Millham, CD, BSC CCPA Goals of this session: 1. Identify the deadly triad in trauma, the goal of damage control resuscitation
More informationP. W. HOWIE M.D., M.R.C.O.G. first method of activation is the intrinsic system. Hageman factor, which in turn activates a series of
Postgraduate Medical Journal (May 1979) 55, 362-366 Blood clotting and fibrinolysis in pregnancy P. W. HOWIE M.D., M.R.C.O.G. MRC Unit of Reproductive Biology, Edinburgh Summary During normal pregnancy,
More informationThe Coagulation Workup In The Office Setting
CAA Conference alm Springs 2012 The Coagulation Workup In The Office Setting CAA Conference alm Springs, October 2012 Robert Miller, A-C Henoch-Schoenlein urpura 1 CAA Conference alm Springs 2012 2 CAA
More informationStrategies for transfusion therapy and monitoring
Strategies for transfusion therapy and monitoring Jakob Stensballe Consultant Anaesthetist & Transfusion Medicine MD PhD Dept. of Anesthesia, Centre of Head and Orthopedics & Section for Transfusion Medicine,
More informationTAYSIDE GUIDE TO MASSIVE TRANSFUSION/BLOOD LOSS
HTC 11/02 TAYSIDE GUIDE TO MASSIVE TRANSFUSION/BLOOD LOSS This local guide should be used in conjunction with the guidelines published by the British Committee for Standards in Haematology. Definition:
More information2017 AABB Annual Meeting On-Demand SAM Sessions
2017 AABB Annual Meeting On-Demand SAM Sessions The following 14 SAM sessions from the 2017 AABB Annual Meeting are eligible for up to 17.75 SAM eligible credits. The number of credits is based on the
More informationROTEM Basic Interpretation Guide
ROTEM Basic Interpretation Guide Parameter: Clotting Time CT - Clotting Time (seconds) The time from the start of the test until first significant levels of a clot are detected. This measurement is initiated
More informationCLINICAL TRIAL PROTOCOL UK VERSION
Tranexamic acid for the treatment of gastrointestinal bleeding: an international randomised, double blind placebo controlled trial CLINICAL TRIAL PROTOCOL UK VERSION Protocol Number: ISRCTN11225767 NUMBER
More information